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c-FLIP is a well-described inhibitor of death 
  receptor–mediated apoptosis (1). At the mRNA 
level, it can be found in multiple splice var-
iants, whereas at the protein level only three 
isoforms, c-FLIPL, c-FLIPS, and c-FLIPR, have 
been detected so far (1–4). All three c-FLIP 
isoforms contain two death eff  ector domains 
(DEDs), which are structurally similar to the 
NH2-terminal part of procaspase-8. c-FLIPL 
also contains catalytically inactive caspase-like 
domains (p20 and p12).
c-FLIP proteins are recruited to the death-
inducing signaling complex (DISC) by DED 
interactions (3–5). Both short c-FLIP isoforms, 
c-FLIPS and c-FLIPR, block death receptor–
  induced apoptosis by inhibiting procaspase-8 
activation at the DISC (2, 3). The role of 
c-FLIPL at the DISC is still a matter of contro-
versy (6, 7). Some reports describe c-FLIPL as 
an antiapoptotic molecule, functioning in a way 
analogous to c-FLIPS, whereas others describe 
c-FLIPL as a proapoptotic molecule, facilitating 
the activation of procaspase-8 at the DISC. This 
proapoptotic role may explain the phenotype of 
c-FLIP–defi  cient mice characterized by heart 
failure and death at embryonic day 10.5. The 
same phenotype has been reported for caspase-8–
and FADD-defi  cient mice (8–11).
In addition to its antiapoptotic role in death 
receptor–induced apoptosis, c-FLIP proteins 
were invoked to play a prominent role in NF-
κB signaling (12–14). The transcription factor 
NF-κB family regulates the expression of genes 
crucial for innate and adaptive immune re-
sponses, cell growth, and apoptosis (15). In 
mammalian cells, the NF-κB family is com-
posed of fi  ve members: RelA, RelB, c-Rel, 
p50/NF-κB1, and p52/NF-κB2 (16). In most 
cells, the NF-κB dimer is sequestered in the 
cytosol by inhibitors of the κB protein (IκB), 
and its nuclear translocation can be induced by 
a wide variety of stimuli (16). These stimuli 
trigger activation of the IκB kinase (IKK) com-
plex, which consists of two catalytic subunits, 
IKKα and IKKβ, as well as a regulatory sub-
unit, IKKγ/NEMO. When the IKK complex 
is activated, IκB is phosphorylated, and the 
IκBs are degraded in a ubiquitin-dependent 
manner. The NF-κB dimers can then be trans-
located into the nucleus, where target gene 
transcription is induced.
Recently, it has been demonstrated that over-
expression of c-FLIPL activates NF-κB (13, 17). 
In another study, upon overexpression, c-FLIPL 
was shown to interact with established compo-
nents of the TNFR-mediated NF-κB activation 
pathway, TRAF1, TRAF2, and RIP (12). In ad-
dition, it has been reported that c-FLIPL–medi-
ated NF-κB activation requires cleavage to 
p43-FLIP, also demonstrated to interact with 
TRAF2 (18). In TNFR-mediated NF-κB acti-
vation, TRAF2 and RIP were described to act 
upstream of the IKK complex (19, 20).
Here, we show that in nonapoptotic cells, 
c-FLIP forms heterodimers with procaspase-8 
resulting in a novel NH2-terminal fragment of 
c-FLIP (p22-FLIP). p22-FLIP turned out to be 
the key mediator of NF-κB activation by 
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direct binding to the IKK complex. These fi  ndings provide 
a new mechanism of c-FLIP–mediated NF-κB activation 
and shed light on the regulation of life/death decisions made 
in lymphocytes.
RESULTS
A new form of c-FLIP can be detected in malignant B and T cells
In addition to the three previously described c-FLIP protein 
isoforms, c-FLIPL, c-FLIPR, and c-FLIPS (2, 3, 21), we have 
detected a new prominent protein band with the anti-FLIP 
mAb NF6 directed against the DED region of c-FLIP (Fig. 
1 A). The molecular mass of this protein is  22 kD. The 
p22 protein was observed in total cellular lysates (Fig. 1 A) 
and in immunoprecipitates (Fig. 1 B) from B lymphoblastoid 
cell lines BoeR and Raji and the T cell lines HUT78 and 
Jurkat A3, but not in CEM and SKW6.4 cells. The viability 
of the cells used for analysis was verifi  ed by negative prop-
idium iodide and annexin V staining (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20051556/DC1). 
P22 protein was the most prominent in BoeR cells (Fig. 1, A 
and B). We call this protein p22-FLIP.
The detection of p22-FLIP with the anti-FLIP mAb 
NF6 indicated the presence of DEDs in p22-FLIP because 
the antibody was raised against the NH2 terminus of c-FLIP. 
Furthermore, p22-FLIP disappeared upon the addition of 
zVAD-fmk (Fig. 1 C). This suggests that p22-FLIP is likely a 
caspase-dependent cleavage product of c-FLIP. We then an-
alyzed the primary structure of c-FLIPL/S and found an aspar-
tate residue at position 198 (Fig. 1 D). Cleavage at Asp198 
could result in the formation of an NH2-terminal DED-
  containing cleavage product with a molecular mass of  22 
kD, corresponding to p22-FLIP.
To test this hypothesis, we generated a cDNA corre-
sponding to the c-FLIP NH2-terminal fragment resulting 
from cleavage at Asp198. Subsequently, p22-FLIP was trans-
lated in vitro and added to cell lysates of BoeR cells, followed 
by immunoprecipitation with the anti-FLIP mAb NF6. The 
products of immunoprecipitation as well as the correspond-
ing lysates were analyzed by Western blot (Fig. 1 E). After 
adding the in vitro–translated c-FLIP NH2-terminal frag-
ment, the band corresponding to p22-FLIP increased consid-
erably. Thus, we conclude that the molecular mass of the in 
vitro–translated product was indeed identical to endogenous 
p22-FLIP. These data provide the fi  rst evidence that p22-
FLIP is an NH2-terminal cleavage product of c-FLIP gener-
ated by cleavage at Asp198.
p22-FLIP identifi  cation as the NH2-terminal cleavage 
product of c-FLIP
To study whether p22-FLIP can be generated from both   
c-FLIPL and c-FLIPS, we performed the following experiment
in vitro. c-FLIPL, c-FLIPS, and FLAG-c-FLIPL were trans-
lated in vitro, [35S] labeled, and added to total cellular lysates 
of HUT78 and J16 cells (Fig. 2 A). Upon incubation, all 
c-FLIPs were cleaved into the NH2-terminal fragment p22-
FLIP (for c-FLIPL and c-FLIPS), the NH2-terminal FLAG-
p22-FLIP (for FLAG-c-FLIPL), and the COOH-  terminal 
fragment p33-FLIP (for c-FLIPL and FLAG-c-FLIPL). 
  Consistent with the results obtained previously, p22-FLIP 
was not detected upon the addition of zVAD-fmk. Thus, we 
observed a caspase-  dependent processing of c-FLIPL/S into 
p22-FLIP in nonapoptotic cells.
To provide conclusive evidence that p22-FLIP is indeed 
the cleavage product of c-FLIP resulting from cleavage at 
Asp198, we generated an uncleavable D198A mutant of 
FLAG-c-FLIPL. In vitro–translated [35S]-labeled D198A-
FLAG-c-FLIPL and WT-FLAG-c-FLIPL were added to the 
lysates of HUT78 cells (Fig. 2 B). As anticipated, FLAG-p22-
FLIP was generated in a caspase-dependent manner only 
from WT-FLAG-c-FLIP. In addition, BoeR cells were trans-
fected with WT- and D198A-FLAG-c-FLIP constructs, and 
consistent with the in vitro data, FLAG-p22-FLIP generation 
was observed only in the cells transfected with the  WT 
Figure 1.  Caspase-dependent presence of p22-FLIP in tumor cell 
lines. (A) Total cellular lysates of the indicated T and B cell lines were 
subjected to 12% SDS-PAGE and Western blot analysis using the anti-FLIP 
mAb NF6. The positions of c-FLIPL, c-FLIPS/R, and p22-FLIP are indicated. 
(B) Western blot analysis of c-FLIP proteins after immunoprecipitation 
from various cell lines (5 × 107 cells each) using anti-FLIP mAb NF6. 
  Positions of c-FLIPS/R and p22-FLIP are indicated. (C) HUT78 and Jurkat 
A3 cells were preincubated with or without 20 μM zVAD-fmk for 30 min. 
Analysis of c-FLIP proteins by Western blot was performed as in A. 
(D) Schematic representation of c-FLIP proteins. DEDs are depicted in 
black. The cleavage site for generation of p22-FLIP (D198) is shown. The 
epitope for anti–c-FLIP mAb NF6 is indicated. (E) The NH2 terminus of 
c-FLIP encoding the amino acids 1–198 was in vitro translated, [35S] 
labeled, and added in the indicated amounts to the lysates of BoeR cells 
as well as to immunoprecipitates of c-FLIP from 5 × 107 BoeR cells.JEM VOL. 203, May 15, 2006  1297
ARTICLE
  construct (Fig. 2 C). Collectively, these data demonstrate that 
p22-FLIP is the NH2-terminal cleavage product of c-FLIP 
generated by caspase cleavage at Asp198.
p22-FLIP is generated by procaspase-8 activity and inhibits 
death receptor–induced apoptosis
To unravel the mechanism of p22-FLIP formation and fi  nd 
the caspase directly involved in c-FLIP processing, we in-
vestigated whether procaspase-8 might generate p22-FLIP. 
Procaspase-8, which, as a proform, was reported to possess cat-
alytic activity (7, 22) and form heterodimers with c-FLIP in 
the cytosol by DED interactions, represented a likely candidate 
(6, 23). Therefore, we immunoprecipitated procaspase-8 from 
HUT78 cells with an anti–caspase-8 mAb and added in vitro–
translated [35S]-labeled c-FLIPL (Fig. 3 A, left). Interestingly, 
we observed cleavage of c-FLIPL into the NH2-terminal frag-
ment p22-FLIP and the COOH-terminal fragment p33-FLIP 
by procaspase-8. The processing was blocked by zVAD-fmk.
To ensure that the mature caspase-8 heterotetramer could 
not process c-FLIP into p22-FLIP, we added recombinant 
active caspase-8 to in vitro–translated c-FLIPL (Fig. 3 A, 
right). As expected, recombinant caspase-8 cleaves c-FLIPL in 
a “classic apoptotic” fashion and generated p43-FLIP and 
p12-FLIP. Thus, we show that caspase-8 and procaspase-8 
process c-FLIP in two mutually exclusive ways. The active 
caspase-8 heterotetramer generates the well-characterized 
p43-FLIP and p12-FLIP cleavage products, whereas procas-
pase-8 activity induces formation of the novel p22-FLIP 
cleavage product as well as the COOH-terminal p33-FLIP. 
This is consistent with a report on diff  erent substrate specifi  c-
ities of the caspase-8 proform and active caspase-8 (7). Clearly, 
the present study is the fi  rst to demonstrate two diff  erent cas-
pase-8 specifi  cities with respect to c-FLIP cleavage.
c-FLIP proteins are well-established inhibitors of death 
receptor–mediated apoptosis. To examine the role of p22-
FLIP in death receptor–mediated apoptosis, we generated sta-
ble BJAB cell lines overexpressing either high (p22-FLIPhigh) 
or low (p22-FLIPlow) amounts of p22-FLIP. The amount of 
p22-FLIP in these cell lines was validated by Western blot 
(Fig. 3 B). Both p22-FLIPhigh and p22-FLIPlow BJAB cells 
were characterized by reduced sensitivity toward CD95- and 
TRAIL-induced apoptosis as compared with the vector-
transfected control (Fig. 3, C and D, respectively). The re-
duction in apoptosis was more prominent in the p22-FLIPhigh 
cells. These data provide evidence that compared with other 
c-FLIP proteins, p22-FLIP is an even stronger inhibitor of 
death receptor–induced apoptosis.
c-FLIP proteins were reported to have a short half-life 
(24, 25). We and others have demonstrated that cyclohexi-
mide (CHX) sensitizes cells toward death receptor–induced 
Figure 2.  Identifi  cation of the p22-FLIP cleavage site. (A) In 
vitro–translated [35S]-labeled c-FLIPS, c-FLIPL, or FLAG-c-FLIPL was 
added to the lysates of HUT78 (left) and Jurkat A3 cells (right) and 
incubated overnight at 4°C in presence or absence of 50 μM zVAD-
fmk. Reactions were separated on 12% SDS-PAGE gels, blotted, and 
subjected to autoradiography. (B) In vitro–translated [35S]-labeled 
WT-FLAG-c-FLIPL or D198A-FLAG-c-FLIPL was added to the lysates of 
HUT78 cells and incubated overnight at 4°C in the presence or absence 
of 50 μM zVAD-fmk and visualized as in A. (C) BoeR cells were trans-
fected with WT-FLAG-c-FLIPL or D198A-FLAG-c-FLIPL and incubated 
with or without 20 μM zVAD-fmk, and c-FLIP proteins were analyzed 
by Western blot.1298  P22-FLIP IS A KEY MEDIATOR OF NF-κB INDUCTION | Golks et al.
Figure 3.  p22-FLIP is generated by procaspase-8 and inhibits 
death receptor–induced apoptosis. (A) Procaspase-8 was immuno-
precipitated from HUT78 cells using anti–caspase-8 mAb C15 and 
then incubated for 1 h at 37°C together with in vitro–translated [35S]-
labeled c-FLIPL in the presence or absence of zVAD-fmk. c-FLIP pro-
cessing was analyzed by autoradiography (top left). c-FLIP cleavage 
products p22 and p33 are indicated. Afterward, the same membrane 
was subjected to Western blot analysis using anti–caspase-8 mAb C15 
(bottom left). [35S]-labeled c-FLIPL was incubated with the indicated 
concentrations of recombinant caspase-8 for 1 h at 37°C. c-FLIP pro-
cessing was analyzed by autoradiography (top right). c-FLIP cleavage 
products p12 and p43 are indicated. Afterward, the same membrane 
was subjected to Western blot analysis using anti–caspase-8 mAb C15 
(bottom right). (B) Analysis of p22-FLIP expression in BJAB cell lines 
stably overexpressing high or low amounts of p22-FLIP (p22-FLIPhigh or 
p22-FLIPlow, respectively). Endogenous expression of c-FLIPS is used as 
a loading control. (C) p22-FLIPhigh, p22-FLIPlow, and vector-transfected 
BJABs (Ctrl.) were stimulated with 1 μg/ml anti–APO-1 antibodies 
or 50 μl/ml LZ-CD95L for 16 h. Specifi  c cell death was calculated as 
described in Materials and methods. (D) p22-FLIPhigh, p22-FLIPlow, and JEM VOL. 203, May 15, 2006  1299
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apoptosis, which correlates with a decrease of c-FLIP levels 
(24, 25). To understand whether sensitization also involves a 
decrease of the p22-FLIP level, we studied Boer cells that 
contain high levels of p22-FLIP. Treatment of Boer cells 
with CHX resulted in a substantial decrease of the p22-FLIP 
level within 4 h (Fig. S2 A, available at http://www.jem.
org/cgi/content/full/jem.20051556/DC1). This decrease 
correlated with an enhanced sensitivity toward CD95- and 
TRAIL-induced apoptosis (Fig. S2 B). These data provide 
additional evidence that the p22-FLIP level in Boer cells cor-
relates with the sensitivity toward death receptor–induced 
apoptosis, pointing toward the inhibitory role of p22-FLIP.
The antiapoptotic action of c-FLIP in death receptor–
mediated apoptosis involves inhibition of caspase-8 activation 
at the DISC (2, 3, 24). To investigate whether p22-FLIP is 
also recruited to the DISC, we immunoprecipitated the 
CD95 DISC from p22-FLIPhigh cells. Indeed, p22-FLIP was 
recruited to the DISC (Fig. 3 E). As expected, the activation 
of procaspase-8 at the DISC of p22-FLIPhigh cells was lower 
than in vector-transfected cells. The amount of caspase-8 
cleavage products in the DISC, p43/p41, and p18 was mark-
edly reduced in p22-FLIPhigh cells, whereas the amounts 
of FADD and CD95 were similar in both p22-FLIPhigh and 
vector-transfected cells. This observation is consistent with 
the reduced sensitivity of p22-FLIPhigh cells toward CD95-
  induced apoptosis and shows that p22-FLIP eff  ectively blocks 
caspase-8 activation at the DISC, thereby inhibiting CD95-
induced apoptosis.
Figure 4.  p22-FLIP is a strong inducer of NF-𝗋B. (A) 293T cells 
were cotransfected with MEKK1, p22-FLIP, c-FLIPL, and luciferase re-
porter plasmid. GFP transfections were performed to control the trans-
fection effi  ciency. Western blot analysis using anti-FLIP mAb NF6 was 
performed to control equal protein expression (right). (B) 293T cells 
were cotransfected with p22-FLIP and the luciferase reporter plasmid. 
After the indicated periods of time, cells were lysed and NF-κB 
  luciferase   activity was determined (top). Western blot analysis using 
anti-FLIP mAb NF6 was performed to determine the expression level 
of p22-FLIP. (C) Nuclear extracts, which were prepared from 293T 
cells transfected with p22-FLIP or GFP, were subjected to EMSAs 
using 32P-labeled oligonucleotides containing an NF-κB (left) 
or an NF-Y (right) binding site. p22-FLIP expression was verifi  ed 
by Western blot.
vector-transfected BJABs (Ctrl.) were stimulated with the indicated 
concentrations of FLAG-TRAIL for 16 h. (E) CD95 DISCs were immuno-
precipitated from 5 × 107 cells of p22-FLIPhigh and vector-transfected 
BJABs (Ctrl.) and analyzed by Western blot with anti–caspase-8 mAb 
C15, anti-FLIP mAb NF6, anti-CD95 polyclonal antibody C20, and anti-
FADD mAb.1300  P22-FLIP IS A KEY MEDIATOR OF NF-κB INDUCTION | Golks et al.
p22-FLIP is a strong inducer of NF-𝗋B
We established an inhibitory role of p22-FLIP in death re-
ceptor–induced apoptosis; however, the questions of why 
p22-FLIP is present in nonapoptotic malignant cells and 
which functional role p22-FLIP might play in the non-
apoptotic scenario were not answered. Using NF-κB lu-
ciferase activation assays with p22-FLIP and c-FLIPL, we 
observed that p22-FLIP is a strong inducer of NF-κB (Fig. 
4 A). Moreover, p22-FLIP–mediated NF-κB activation 
was much stronger than that observed with c-FLIPL, even 
though expression levels of p22-FLIP and c-FLIPL were 
similar (Fig. 4 A).
To clarify whether NF-κB activation correlates with the 
expression level of p22-FLIP, we performed transient trans-
fections of 293T cells with p22-FLIP (Fig. 4 B). The maxi-
mum of NF-κB activity at 10 h paralleled the increase of 
p22-FLIP expression. Moreover, the observed expression 
level of p22-FLIP in 293T cells (Fig. 4 B) compared with 
c-FLIPL was still lower as compared with the ratio p22-FLIP/
c-FLIPL in BoeR cells (Fig. 1 A). Thus, we demonstrate that 
the induction of NF-κB is specifi  c for p22-FLIP and does not 
depend on a high expression level of p22-FLIP.
We also assayed p22-induced NF-κB activity by elec-
trophoretic mobility shift assay (EMSA; Fig. 4 C), which 
independently confi   rmed that p22-FLIP induces NF-κB. 
Thus, we demonstrated that p22-FLIP is a strong inducer 
of NF-κB.
p22-FLIP induces NF-𝗋B by direct interaction 
with the IKK complex
To get more insight into the mechanism of p22-mediated 
NF-κB induction, we coexpressed p22-FLIP with the in-
hibitors of NF-κB (IκBα and IκBβ) and with components 
of the IKK complex (IKKα, IKKβ, DN-IKKα, and DN-
IKKβ; Fig. 5 A). Cotransfections of p22-FLIP with increas-
ing amounts of IκBα and IκBβ inhibited NF-κB activation. 
Looking at more upstream events, we observed that cotrans-
fection with DN-IKKα and DN-IKKβ also led to suppres-
sion of NF-κB activation. Collectively, the results indicated 
that p22-FLIP is a strong inducer of NF-κB acting via the 
canonical NF-κB pathway.
We further examined whether p22-FLIP directly inter-
acts with the IKK complex. FLAG-tagged IKKα, IKKβ, 
and IKKγ were transiently cotransfected with p22-FLIP into 
293T cells, and then immunoprecipitated with anti-FLAG 
and anti-FLIP antibodies (Fig. 5 B). We did not observe any 
interaction between p22-FLIP and IKKα or IKKβ. However, 
p22-FLIP was coimmunoprecipitated with FLAG-IKKγ and 
vice versa. Thus, we showed that p22-FLIP interacts with the 
IKK complex via IKKγ.
In addition, we compared NF-κB induction by p22-
FLIP, c-FLIPL, and p43-FLIP upon transient transfections in 
293T cells (Fig. 5 C). Interestingly, the addition of zVAD-
fmk resulted in a decrease in NF-κB activation for p43-FLIP 
and c-FLIPL, but did not aff  ect p22-FLIP–mediated NF-κB 
induction. These results strongly indicate that p43-FLIP and 
c-FLIPL require further cleavage to induce NF-κB activity, 
whereas p22-FLIP does not. Thus, we show that for the in-
duction of NF-κB activity, both p43-FLIP and c-FLIPL have 
to be processed into p22-FLIP.
Figure 5.  p22-FLIP induces NF-𝗋B by direct interaction with the 
IKK complex. (A) 293T cells were cotransfected with luciferase reporter 
plasmid and either MEKK1, p22-FLIP, or c-FLIPL (top part of the diagram). 
293T cells were cotransfected with p22-FLIP, the luciferase reporter plas-
mid, and any one of the constructs IκBα, IκBβ, WT-IKKα, WT-IKKβ, mu-
tated IKKα, or IKKβ (bottom part of the diagram). Transfection effi  ciency 
was examined using GFP transfections. NF-κB luciferase activity was 
determined as described in Materials and methods. (B) FLAG or FLIP im-
munoprecipitations were performed from 293T cells that were transfected 
with p22-FLIP and any one of the constructs FLAG-IKKα, FLAG-IKKβ, or 
FLAG-IKKγ. Immunoprecipitated products were subjected to 12% SDS-
PAGE gels and analyzed by Western blot using anti-FLIP mAb NF6 and 
anti-FLAG mAb. (C) 293T cells were cotransfected with MEKK1, p22-FLIP, 
c-FLIPL, p43-FLIP, and the luciferase reporter plasmid. Transfected cells 
were incubated for 16 h in the presence of the indicated concentrations 
of zVAD-fmk and lysed, and NF-κB luciferase activity was determined.JEM VOL. 203, May 15, 2006  1301
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p22-FLIP induces NF-𝗋B during activation of primary 
lymphocytes and maturation of primary DCs
Next, we examined primary human T and B cells for the 
presence of p22-FLIP. Interestingly, p22-FLIP was absent in 
freshly prepared cells, but was generated upon activation of 
these cells with PHA (Fig. 6 A). The same phenomenon was 
observed in DCs. p22-FLIP was generated upon LPS stimu-
lation, indicating that p22-FLIP is present during maturation 
of DCs (Fig. 6 A). Also, the increase of p22-FLIP levels in 
primary cells correlated with the increase of c-FLIP levels 
and, correspondingly, with the increase of the ratio of c-FLIP 
to procaspase-8. This observation provides additional evi-
dence for the proposed mechanism of procaspase-8–  mediated 
c-FLIP cleavage to p22-FLIP (Fig. 3).
To fi  nd out whether p22-FLIP also directly interacts with 
the IKK complex in primary human T cells, we performed 
immunoprecipitations using an anti-IKKγ  antibody (Fig. 
6 B). We observed p22-FLIP in the IKK complex. Thus, we 
conclude that p22-mediated NF-κB induction occurs via the 
same mechanism in primary cells.
To obtain more insight into the role of p22-FLIP in 
T cell activation, we studied the proliferation of primary 
T cells upon silencing of c-FLIP using small interfering RNA 
(siRNA). The silencing of c-FLIP resulted in down-  regulation 
of c-FLIPL/S/R as well as its cleavage product, p22-FLIP (Fig. 
6 C). Primary T cells were stimulated with either PHA or 
anti-CD3/CD28, and thymidine incorporation was mea-
sured after 3 d of additional culture (Fig. 6 C). Interestingly, 
Figure 6.  p22-FLIP is a key mediator of NF-𝗋B induction. (A) 
Primary human T and B cells were stimulated with 1 μg/ml PHA. Primary 
immature iDCs were stimulated with 500 ng/ml LPS. Western blot analy-
sis was performed using the anti-FLIP mAb NF6, the anti–caspase-8 
mAb C15, and the anti-ERK1 mAb. (B) 107 primary human T cells were 
stimulated with 1 μg/ml PHA for 12 h and lysed, and anti-IKKγ immuno-
precipitation was performed. Western blot analysis was performed using 
anti-IKKα/β antibody and anti-FLIP mAb NF6. (C) Primary human T cells 
were transiently transfected with double-stranded siRNA oligonucleo-
tides comprising a FLIP-specifi  c sequence (FLIP-1) or a nonspe-
cifi  c sequence (Ctrl.). 48 h after transfection, cells were stimulated with 
1 μg/ml PHA for 3 d (right) or 0.5 μg/ml anti-CD3/28 for 24 h (left) or 
3 d (right). After incubation, cells were lysed and Western blot analysis 
was performed using the anti-FLIP mAb NF6 (left), or the proliferation 
was measured after incorporation of tritiated thymidine ([3H]TdR) during 
the last 18 h.1302  P22-FLIP IS A KEY MEDIATOR OF NF-κB INDUCTION | Golks et al.
silencing of c-FLIP led to a complete stop of cell proliferation. 
Thus, we show that the absence of c-FLIP and, consequently, 
p22-FLIP led to severe defects in T cell proliferation.
DISCUSSION
c-FLIP proteins were demonstrated to induce NF-κB ac-
tivation (12–14). However, the exact underlying mecha-
nism of this process has not been established yet. In this 
study, we identifi  ed a new mechanism of c-FLIP–mediated 
NF-κB activation and showed that NF-κB activation requires 
c-FLIP processing into the NH2-terminal DED-  containing 
fragment, p22-FLIP (Fig. 7). p22-FLIP is generated by 
  procaspase-8 cleavage of both c-FLIP isoforms, c-FLIPL 
and c-FLIPS.   Furthermore, p22-FLIP is a strong activator of 
NF-κB, acting directly at the level of the IKK complex by 
binding to IKKγ. In addition to its role as an activator of 
NF- κB, p22-FLIP can block apoptosis by directly binding 
to the DISC.
p22-FLIP is generated by cleavage of c-FLIPL/S at Asp198. 
The resulting NH2-terminal fragment, p22-FLIP, contains 
two tandem DEDs and has a high structural homology to 
v-FLIP of the Kaposi’s sarcoma-associated herpesvirus and 
other v-FLIPs (14) that are also characterized by the presence 
of two DEDs followed by a short COOH terminus.
We argue that p22-FLIP is the fi  nal cleavage product of 
c-FLIP that serves as a mediator of NF-κB activation. This 
result is in contrast to previous studies, where it was sug-
gested that p43-FLIP is a cleavage product of c-FLIP that 
mediates NF-κB activation (18). We have clearly shown that 
upon zVAD-fmk treatment, p43-FLIP–mediated activation 
of NF-κB is decreased, whereas the p22-FLIP–mediated NF-
κB response remained unaltered. These results indicate that 
p43-FLIP requires further processing.
Importantly, our study demonstrates a new NF-κB–
  activating pathway initiated by procaspase-8. We show that 
independently of death receptor stimulation, procaspase-8 
generates the p22-FLIP cleavage product, which leads to 
the induction of NF-κB (Fig. 7). Recently, procaspase-8 
was reported to play a prominent role in NF-κB induction 
via its involvement in the MALT1–Bcl-10 adaptor com-
plex that is formed upon TCR stimulation (26). Our fi  nd-
ings further elucidate the involvement of procaspase-8 in 
NF-κB induction.
Interestingly, we could also show that the active mature 
caspase-8 heterotetramer p102-p182 cleaves c-FLIPL in vitro 
to p43-FLIP and p12-FLIP, but not to p22-FLIP. Thus, we 
observe that procaspase-8 and caspase-8 heterotetramer cleave 
c-FLIP in two diff  erent ways. This is consistent with reports 
upon diff  erent substrate specifi  cities of the caspase-8 proform 
and active caspase-8 (7). Of note, our study is the fi  rst one 
demonstrating two diff  erent caspase-8 specifi  cities with re-
spect to c-FLIP cleavage.
In addition, we have observed in primary cells that upon 
increase of the ratio of c-FLIP to procaspase-8, the amount of 
p22-FLIP was substantially increased. It is likely that procas-
pase-8 constitutively cleaves c-FLIP to p22-FLIP, forming 
dimers with c-FLIP. The formation of such dimers between 
procaspase-8 and c-FLIP in the cytosol was described previ-
ously (6, 23). Thus, the ratio of procaspase-8 to c-FLIP in a 
particular cell type would be the crucial factor defi  ning the 
amount of generated p22-FLIP and, correspondingly, the 
potential to induce NF-κB.
Our fi  ndings provide a molecular mechanism for how 
c-FLIP and procaspase-8 contribute to the activation and pro-
liferation of primary lymphocytes. It was reported that caspase 
activity is essential for T cell activation, as it was shown in 
experiments with caspase inhibitors (27, 28). Analysis of cas-
pase-8 and c-FLIP conditional knockout mice has demon-
strated that those mice show severe defects in T cell activation 
and proliferation (29). Caspase-8 was reported to be essential 
for antigen-induced NF-κB activation in T, B, and NK cells 
(26, 30, 31). We show that upon silencing of c-FLIP in pri-
mary cells, the proliferation of these cells is impaired. This 
demonstrates the importance of our new p22-FLIP–medi-
ated NF-κB–activating pathway in primary lymphocytes.
In conclusion, we described a new NF-κB–activating 
pathway, which is mediated by two well-described apoptotic 
DED-containing proteins: procaspase-8 and c-FLIP via their 
cleavage product, p22-FLIP. The balance between DED-
containing proteins may provide sensitive signaling check 
points that cells use for signaling cross-talk and switching be-
tween apoptosis-resistant and -sensitive  phenotypes and, 
thus, between life and death.
MATERIALS AND METHODS
Cell lines. The T cell lines HUT78, CEM, H9, Jurkat (clone A3), and 
  Jurkat (clone J16); the B lymphoblastoid cell lines SKW6.4, Raji, and BJAB; 
and the pre–B cell line BoeR were maintained in RPMI 1640, 10 mM 
Hepes, 50 μg/ml gentamycin, and 10% fetal calf serum (all from Life 
  Technologies) in 5% CO2.
Figure 7.  The dual function of p22-FLIP in the cell. p22-FLIP 
 induces  NF-κB by interacting with IKKγ in the IKK complex (right side). 
In addition, p22-FLIP can block death receptor–mediated apoptosis by 
binding to the DISC via DED interactions and inhibiting procaspase-8 
  activation (left side).JEM VOL. 203, May 15, 2006  1303
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Antibodies and reagents. Anti-FADD mAb (IgG1) was purchased from 
Transduction Laboratories. Anti-FLAG mAb was purchased from Sigma-
Aldrich. Anti-CD95 polyclonal antibody C20 was purchased from Santa 
Cruz Biotechnology, Inc. Anti–caspase-8 mAb C15 (mouse IgG2b) recog-
nizes the p18 subunit of caspase-8 (32). Anti-IKKα/β and anti-IKKγ anti-
bodies were purchased from Santa Cruz Biotechnology, Inc., and anti-ERK1 
mAb was purchased from BD Biosciences. Anti–APO-1 is an agonistic mAb 
(IgG3, κ) recognizing an epitope on the extracellular part of CD95 (APO-
1/Fas; reference 33). FLAG-TRAIL was obtained from H. Walczak (DKFZ, 
Heidelberg, Germany). Horseradish peroxidase–conjugated goat anti–mouse 
IgG1, IgG2a, and IgG2b were from SouthernBiotech. All chemicals used 
were of analytical grade and purchased from Merck or Sigma-Aldrich. Plas-
mids encoding c-FLIPL and c-FLIPS have been described previously (2). The 
plasmid encoding FLAG-c-FLIPL has also been described (3). NF-κB 
  reporter plasmid was provided by M. Li-Weber (DKFZ, Heidelberg, 
  Germany). Constructs of FLAG-IKKα, FLAG-IKKβ, DN-FLAG-IKKα 
(Κ44Α), and DN-FLAG-IKKβ (Κ44Α) were provided by H. Nakano (Jun-
tendo University, Tokyo, Japan).
EMSA. Soluble nuclear proteins were prepared and used for EMSA as 
described previously (34). For each reaction, 10–20 fmol of 32P-labeled 
oligonucleotides comprising an NF-κB binding site (5′-T  C  A  G  A  G  G  G  G  A  C-
T  T  T  C  C  G  A  G  A  G  G  C  G  -3′) or NF-Y binding site (5′-C  A  C  C  T  T  T  T  A  A  C  C-
A  A  T  C  A  G  A  A  A  A  A  T  -3′) were used.
Cloning of p22-FLIP and D198A-FLAG-c-FLIPL. p22-FLIP was 
cloned into the pEF4 expression vector (Invitrogen) using the PCR and the 
following primers: sense (encoding the KpnI restriction site): 5′-ggggtacccc-
A  T  G  T  C  T  G  C  T  G  A  A  G  T  C  A  T  C  C  -3′ and antisense (encoding the XbaI 
  restriction site): 5′-gctctagagcctaA  T  C  C  T  T  G  A  G  A  C  T  C  T  T  T  T  G  G  -3′.
The D198A-FLAG-c-FLIPL mutant was cloned via overlap-PCR into 
the pEF4 expression vector (Invitrogen). The NH2-terminal part was ampli-
fi  ed using the following: forward primer 1: 5′-ggggtaccccA  T  G  G  A  C  T  A  C  A-
A  G  G  A  C  G  A  C  G  A  C  A  A  G  G  G  G  A  T  G  T  C  T  G  C  T  G  A  A  G  T  C  A  T  C  C  A  T  C  A  G  G  -3′; 
reverse primer 1: 5′-C  C  T  G  A  A  A  G  T  T  A  T  T  T  G  A  A  G  G  T  G  C  C  T  T  G  A  G  A  C  T-
C  T  T  T  T  G  G  -3′. The COOH-terminal part was amplifi  ed using the following: 
reverse primer 2: 5′-gctctagagcC  T  A  T  G  T  G  T  A  G  G  A  G  A  G  G  A  T  A  A  G  -3′; 
forward primer 2: 5′-C  C  A  A  A  A  G  A  G  T  C  T  C  A  A  G  G  C  A  C  C  T  T  C  A  A  A  T  A  A-
C  T  T  C  A  G  G  -3′. The overlap-PCR was performed using the forward and 
reverse primer 2.
CD95 DISC analysis. Composition of the CD95 DISC was determined as 
follows. 5 × 107 cells were treated either with 1 μg/ml anti–APO-1 (IgG3) 
for 5 min at 37°C or left untreated, washed twice in 1× PBS, and lysed in 
lysis buff  er (30 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM 
phenylmethylsulfonyl fl  uoride [Sigma-Aldrich], protease inhibitor cocktail 
[Roche], 1% Triton X-100 [Serva], and 10% glycerol). If pretreated with 
zVAD-fmk, cells were preincubated for 30 min at 37°C with the indicated 
concentrations of zVAD-fmk before stimulation. CD95 was immuno-
precipitated with anti–APO-1 and protein A–Sepharose beads (Sigma-
  Aldrich) overnight at 4°C. Beads were washed fi  ve times with 20 volumes of 
lysis buff  er. Immunoprecipitates were used for in vitro assay or analyzed 
  using SDS-PAGE gels (35). Gels were transferred to Hybond nitrocellulose 
membrane (GE Healthcare), blocked with 5% nonfat dry milk in PBS/
Tween (PBS plus 0.05% Tween 20) for 1 h, washed with PBS/Tween, and 
incubated with the primary antibody in PBS/Tween overnight at 4°C. Blots 
were developed with a chemoluminescence method according to the manu-
facturer’s protocol (PerkinElmer).
Immunoprecipitations. For c-FLIP immunoprecipitation, 5 × 107 cells 
were lysed in a volume of 1 ml for 30 min at 0°C, followed by the addition 
of 100 μl NF6 hybridoma supernatant together with 30 μl protein A–
  Sepharose. For FLAG immunoprecipitation, 2 × 106 cells were transfected 
using the calcium phosphate method 1 d before lysis. Immunoprecipitation 
was performed by using 4 μg anti-FLAG mAb together with 30 μl protein 
A–Sepharose. For IKKγ immunoprecipitation, 107 primary human T cells 
were lysed with or without stimulation, and the immunoprecipitation was 
performed by using 2 μg anti-IKKγ mAb together with 30 μl protein A– 
Sepharose. Immunoprecipitations were performed for 1 h at room tempera-
ture or overnight at 4°C. Beads were then washed fi  ve times with 20 volumes 
of lysis buff  er and subjected to Western blot analysis as described above.
In vitro c-FLIP cleavage assays. Lysates of the indicated cell lines were 
prepared as described above and incubated with in vitro–translated [35S]-
  labeled c-FLIPL, FLAG-c-FLIPL, D198A-FLAG-c-FLIPL, or c-FLIPS (TNT, 
T7-coupled reticulocyte lysate system; Promega) overnight at 4°C (36). The 
procaspase-8 cleavage assay was performed as follows: 5 × 107 HUT78 cells 
were lysed, and procaspase-8 was immunoprecipitated using 100 μl anti–
  caspase-8 C15 hybridoma together with 30 μl protein A–Sepharose. Beads 
with bound procaspase-8 were incubated in reaction buff  er (50 mM Hepes, 
pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM dithiothreitol, and 10% 
  sucrose) for 1 h at 37°C together with in vitro–translated c-FLIPL. The re-
combinant caspase-8 cleavage assay was performed as follows: 5 or 50 ng/ml 
recombinant caspase-8 was incubated in reaction buff  er for 1 h at 37°C to-
gether with in vitro–translated c-FLIPL. Reactions were separated on 12% 
SDS-PAGE gels, blotted, and subjected to autoradiography.
Transfection of BJAB and BoeR cells. Stable transfection of BJAB as 
well as transient transfection of BoeR cells was performed using expression 
vectors or the empty vector by electroporation (950 μF, 200 V). Selection 
pressure was added 48 h after transfection (100 μg/ml zeocin) for 2 wk 
(BJAB cells) or 10 d (BoeR cells). Expression was controlled by Western blot 
using anti-FLIP mAb NF6. The p22-FLIP–expressing BJABs as well as the 
empty vector–transfected control cells were subcloned.
Cytotoxicity assay. To assay apoptosis, 5 × 105 cells were incubated in 
48-well plates with or without the indicated amounts of anti–APO-1, LZ- 
CD95L, or FLAG-TRAIL for 16 h at 37°C. Cell death was measured by 
FSC/SSC via fl   ow cytometry, and specifi   c cell death was calculated as 
  follows: (percentage of experimental cell death − percentage of spontaneous 
cell death)/(100 − percentage of spontaneous cell death) × 100.
NF-𝗋B activation assay. The day before transfection, 24-well titer plates 
were seeded with 0.5 × 105 293T cells. The cells were transfected using 
the calcium phosphate method with various expression vectors together 
with 500 ng of the NF-κB–driven luciferase reporter plasmid. Cells were 
washed with PBS 16 h after transfection and lysed for 20 min at room 
temperature in 50 μl lysis buff  er (passive lysis buff  er; Promega), followed 
by centrifugation (10,000 g) for 20 min to sediment insoluble materials. A 
total of 5 μl of cell lysates was mixed with 50 μl of the luciferase assay mix-
ture (470 μM Beetle Luciferin [Promega], 1.07 mM (MgCO3)4Mg(OH)2 × 
5 H2O, 20 mM N-Tris-(hydroxymethyl)-methylglycine, 2.67 mM 
MgSO4, 100 μM EDTA, 33.3 mM DTT, 270 μM CoA(OAc), and 530 μM 
ATP), and relative light units were measured with a Berthold duolu-
minomat (Bad Wildbad).
Preparation and activation of primary human lymphocytes and 
DCs. Human peripheral T and B cells were prepared as described previ-
ously (37). For activation, resting primary human T cells (day 0) were cul-
tured at 2 × 106 cells/ml with 1 μg/ml PHA for 16 h (day 1), and primary 
human B cells (day 0) were cultured at 2 × 106 cells/ml with 2 μg/ml PHA. 
After preparing lymphocytes, the primary human monocytes were isolated 
using cell adhesion onto cell culture fl  asks. Leukocytes were resuspended in 
20–30 ml RPMI 1640 with 10% FCS, and 2-ml aliquots were seeded into 
six-well titer plates. After incubation for 1 h, adherent cells were washed 
with PBS. Monocytes were diff  erentiated into immature DCs by adding 1% 
human AB serum, 1% donor plasma, 1,000 U/ml GM-CSF (Schering), and 
500 U/ml IL-4 (Immunotools) for 3 d. Cytokines were renewed after 3 d 
for an additional 3 d, and immature DCs were stimulated with 500 ng/ml 
LPS for 16 h.1304  P22-FLIP IS A KEY MEDIATOR OF NF-κB INDUCTION | Golks et al.
CHX experiments. For CHX treatments, cells were incubated with 
10 μg/ml CHX for the indicated periods of time. For assaying apoptosis in 
a cytotoxicity assay, 106 cells were pretreated with 10 μg/ml CHX for 4 h, 
washed, and incubated with the indicated concentrations of 1 μg/ml anti– 
APO-1 or 50 ng/ml FLAG-TRAIL for 16 h at 37°C in 24-well plates. Cell 
death was measured by FSC/SSC via fl  ow cytometry, and specifi  c cell 
death was calculated as follows: (percentage of experimental cell death − 
percentage of spontaneous cell death)/(100 − percentage of spontaneous 
cell death) × 100.
Annexin V and propidium iodide staining. To detect phosphatidylser-
ine exposure by fl  ow cytometry, the T and B cell lines were washed once 
with PBS, incubated for 10 min on ice in 400 μl binding buff  er (2.5 mM 
Hepes–NaOH, pH 7.4, 35 mM NaCl, and 0.625 mM CaCl2) with 1 μl 
  annexin V–FITC (Qbiogene) or 10 μg/ml propidium iodide (Invitrogen), 
and analyzed via fl  ow cytometry.
siRNA-mediated knockdown of c-FLIP and proliferation assays. 
  Primary human T cells were transfected by HiPerfect (QIAGEN) with a 
  negative control or siRNA oligonucleotids specifi  c for human CFLAR 
(Hs_CFLAR_1 HP; QIAGEN). For the lipofection, 0.2 μg (75 nM) siRNA 
was used, and transfected cells were rested for 48 h before further analysis. For 
proliferation assays, 105 cells were seeded into a 96-well titer plate and stimu-
lated with either 1 μg/ml PHA or 0.5 μg/ml each of anti-CD3/CD28 for up 
to 4 d. Proliferation was measured with a scintillation counter after tritiated 
thymidine ([3H]TdR) incorporation during the fi  nal 15–18 h of the culture.
Online supplemental material. Fig. S1 shows the living status of tumor cell 
lines used, and Fig. S2 shows that the resistance of BoeR cells toward CD95- or 
TRAIL-induced apoptosis is mediated by c-FLIP. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20051556/DC1.
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